Search

Age-specific definitions for acute respiratory distress syndrome (ARDS) are available, including a specific definition for neonates (the "Montreux definition"). The epidemiology of neonatal ARDS is unknown. The objective of this study was to describe the epidemiology, clinical course, treatment, and outcomes of neonatal ARDS.

The burden of bronchiectasis is disproportionately high in Aboriginal adults, with early mortality. Bronchiectasis precursors, that is, protracted bacterial bronchitis and chronic suppurative lung disease, often commence in early childhood.

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide.

As part of the accelerated development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant justification study of SCB-2019, a protein subunit vaccine candidate containing a stabilised trimeric form of the spike (S)-protein (S-Trimer) combined with two different adjuvants.

Global circulation of respiratory syncytial virus (RSV) is shaped by human air travel with travellers hosting new strains fuelling transmission across borders, an international The Kids Research Institute Australia study found.

Four outstanding members of The Kids Research Institute Australia family – three researchers and an Aboriginal Elder co-researcher – have been named in the Australia Day Honours List for their outstanding service to research and the community.

Experts are warning Aboriginal parents in Western Australia with newborn babies to be vigilant about Respiratory Syncytial Virus (RSV) as winter progresses.

A world-first study has found a new vaccine against potentially deadly respiratory syncytial virus (RSV) is safe and effective for use in pregnant women, to help protect their babies.

World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.

Researchers using powerful microscopes have identified bacterial slime in the lungs of some children with persistent wet coughs.